Company & Sponsor Intelligence
BioMarin Pharmaceutical
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
neuromuscularother_neurology
Indexed studies
NCT01889862Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
other_neurology · United StatesPHASE3
other_neurology · United StatesPHASE3
NCT03505125A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
other_neurology · United StatesCOMPLETED
other_neurology · United StatesCOMPLETED
NCT02636686Extension Study of Drisapersen in DMD Subjects
neuromuscular · United StatesNO_LONGER_AVAILABLE
neuromuscular · United StatesNO_LONGER_AVAILABLE
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →